The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD Patients: Novel insight using functional respiratory imaging

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 28, Issue 2, 2015, Pages 88-99

  De Backer, Jan ^a   Vos, Wim ^a   Vinchurkar, Samir ^a   Van Holsbeke, Cedric ^a   Poli, Gianluigi ^b   Claes, Rita ^c   Salgado, Rodrigo ^c   De Backer, Wilfried ^c  

^a FLUIDDA NV   (Belgium)

^b Chiesi Pharmaceutici   (Italy)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; AEROSOL; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FORMOTEROL FUMARATE; GLUCOCORTICOID; POWDER;

ADULT; AGED; AIRWAY; ARTICLE; BODY PLETHYSMOGRAPHY; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTATIONAL FLUID DYNAMICS; DRUG EFFECT; DRUG FORMULATION; DYSPNEA; FEMALE; HUMAN; HYPERINFLATION; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; OUTCOME ASSESSMENT; SPIROMETRY; TOTAL LUNG CAPACITY; VERY ELDERLY; AEROSOL; CHEMISTRY; COMPUTER ASSISTED DIAGNOSIS; CONVALESCENCE; DRUG EFFECTS; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; LUNG; MEDICINAL CHEMISTRY; PARTICLE SIZE; PATHOPHYSIOLOGY; PILOT STUDY; POWDER; PREDICTIVE VALUE; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RADIOGRAPHY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VITAL CAPACITY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AEROSOLS; AGED; AGED, 80 AND OVER; BECLOMETHASONE; BRONCHODILATOR AGENTS; CHEMISTRY, PHARMACEUTICAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; GLUCOCORTICOIDS; HUMANS; LUNG; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PARTICLE SIZE; PILOT PROJECTS; PLETHYSMOGRAPHY, WHOLE BODY; POWDERS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84926335821     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1064     Document Type: Article

References (21)

1. Cazzola M, and Dahl R: Inhaled combination therapy with long-Acting beta 2-Agonists and corticosteroids in stable COPD. Chest. 2004;126:220-237.
2. Hogg JC: Chronic obstructive pulmonary disease: An overview of pathology and pathogenesis. Novartis Found Symp. 2001;234:4-19; discussion 19-26.
3. Kuwano K, Bosken CH, Paré PD, Bai TR, Wiggs BR, and Hogg JC: Small airways dimensions in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;148:1220-1225.
4. Bosken CH, Wiggs BR, Paré PD, and Hogg JC: Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis. 1990;142:563-570.
5. Paré PD, Brooks LA, Coppin CA, Wright JL, Kennedy S, Dahlby R, Mink S, and Hogg JC: Density-dependence of maximal expiratory flow and its correlation with small airway disease in smokers. Am Rev Respir Dis. 1985;131: 521-526.
6. Grenier PA, Beigelman-Aubry C, Fétita C, Prěteux F, Brauner MW, and Lenoir S: New frontiers in CT imaging of airway disease. Eur Radiol. 2002;12:1022-1044.
7. De Backer JW, Vos WG, Vinchurkar SC, Claes R, Drollmann A, Wulfrank D, Parizel PM, Germonpré P, and De Backer W: Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. Radiology. 2010; 257:854-862.
8. De Backer L, Vos W, De Backer J, Van Holsbeke C, Vinchurkar S, and De Backer W: The acute effect of budesonide/formoterol in COPD patients: A multi-slice computed tomography and lung function study. Eur Respir J. 2012; 40:298-305.
9. De Backer L, Vos W, Salgado R, De Backer J, Devolder A, Verhulst S, Claes R, Germonpre P, and De Backer W: Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD. Int J Chron Obstruct Pulmon Dis. 2011;2011:6:637-646.
10. De Backer JW, Vos WG, Devolder A, Verhulst SL, Germonpreé P, Wuyts FL, Parizel PM, and De Backer W: Computational fluid dynamics can detect changes in airway resistance in asthmatics after acute bronchodilation. J Biomech. 2008;41:106-113.
11. Hanania NA: The impact of inhaled corticosteroid and long-Acting beta-Agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther. 2008;21:540-550.
12. Mahler DA, Wire P, Horstman D, Chang C-N, Yates J, Fischer T, and Shah T: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166: 1084-1091.
13. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, and Olsson H: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J Off J Eur Soc Clin Respir Physiol. 2003;21:74-81.
14. Kardos P, Wencker M, Glaab T, and Vogelmeier C: Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:144-149.
15. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, and Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356: 775-789.
16. Bousquet J, and Dell'anna C: Modulite technology in the development of formoterol HFA pMDI: Clinical evidence and future opportunities. Expert Rev Respir Med. 2008; 2:27-36.
17. Janssens HM, and Tiddens HAWM: Aerosol therapy: The special needs of young children. Paediatr Respir Rev. 2006;7:S83-85.
18. De Backer W, Devolder A, Poli G, Acerbi D, Monno R, Herpich C, Sommerer K, Meyer T, and Mariotti F: Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv. 2010;23:137-148.
19. De Backer JW, Vos WG, GorléCD, Germonpré P, Partoens B, Wuyts FL, Parizel PM, and De Backer W: Flow analyses in the lower airways: Patient-specific model and boundary conditions. Med Eng Phys. 2008;30:872-879.
20. Weuthen T, Roeder S, Brand P, Müllinger B, and Scheuch G: In vitro testing of two formoterol dry powder inhalers at different flow rates. J Aerosol Med. 2002;15:297-303.
21. Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini EM, and Olivieri D: Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients. Int J Chron Obstruct Pulmon Dis. 2011;6:503-509.